Finance-Funding

  1. Tackling Cell & Gene Therapy Financing & Manufacturing Challenges 7/1/2019

    As interest in the cell and gene market continues to heat up, the sector’s manufacturing and finance challenges have become top priorities.

  2. Making Sense Of New Accounting And Financial Reporting Changes 5/31/2019

    A summary of some key sections of version 10 of Deloitte’s Life Sciences Accounting And Financial Reporting Update—Including Interpretive Guidance.

  3. The Rollercoaster Ride Of A Biotech CEO 4/1/2019

    Sam Cobb, managing director and CEO of Australian biotech AdAlta, talks about how the company has struggled to procure funding over the years and the strategies they employed to finally get listed on the Australian Securities Exchange.

  4. Paving The Way For Future Funding 3/1/2019

    Growing a life sciences company will have continuous demands for funding. Wherever that money comes from, undertaking a commitment to PCAOB (Public Company Accounting Oversight Board) compliance will be valued by potential investors.

  5. The Drug-Delivery Company That Partnerships Built 2/1/2019

    “Normally a company raises money, does their science, and hopes to get a deal. We were the inverse of that,” explains Joseph Payne, president and CEO of Arcturus Therapeutics.

  6. Is China’s Golden Era Ending? 1/2/2019

    The value of China’s biotechs fell some 30 percent since the trade war began, and VC funding, while strong, slipped before that. Interest in China, however, remains strong.

  7. How Biopharma & Medtech CFOs Are Viewing U.S. Tax Reform 1/2/2019

    Biopharma and medtech companies are expecting mostly positive results from the new Tax Cuts and Jobs Act (TCJA), according to research by The Deloitte Center for Health Solutions and Forbes Insights.

  8. How To Put A Price Tag On Emerging Therapies 11/7/2018

    There’s no doubt that partnerships and M&As are key growth drivers in the biopharma industry.  But for collaborative relationships to occur, understanding the value of a company’s underlying assets is critical.

  9. Serendipity: When Funders Found A Company 10/4/2018

    Foghorn Therapeutics is managing to sidestep some of the growing pains common to early companies, thanks to its genesis as a VC-founded company.

  10. When Should Tax Functions Be Brought In-House? 8/2/2018

    At what stage of a biopharma’s growth does it makes sense to bring on an internal tax function? The answer, of course, varies significantly, but here are some factors to consider when making this important business decision.